New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 1, 2014
13:57 EDTCELGCelgene announced updated OS results from post-hoc analysis of Abraxane study
Celgene announced updated Overall Survival, OS, results from a post-hoc analysis of its phase III IMPACT, Metastatic Pancreatic Adenocarcinoma Clinical Trial, study of ABRAXANE, paclitaxel protein-bound particles for injectable suspension, in combination with gemcitabine in treatment-na´ve patients with metastatic pancreatic cancer. A poster discussion of the analysis is scheduled for Sunday, June 1st at 11:30 am CT at the 50th American Society of Clinical Oncology, ASCO, annual meeting in Chicago, Ill. The analysis also showed that the treatment effect on OS for pre-specified subgroups analyzed in the trial remained consistent across patient subgroups. Specifically, patients with Karnofsky Performance Status, KPS, KPS 90-100 had a higher median OS on ABRAXANE plus gemcitabine as compared to gemcitabine alone [median OS 9.7 months vs. 7.9 months. Patients with KPS 70-80 also maintained a benefit [median OS 7.6 months vs. 4.3 months. This updated analysis also evaluated the prognostic effects of CA19-9 and neutrophil-to-lymphocyte ratio, NLR. Both elevated CA19-9 and elevated NLR were associated with poorer survival. Further, treatment with ABRAXANE plus gemcitabine appeared to reduce the effect of CA19-9 as a poor prognostic factor, as similar overall survival was observed regardless of CA19-9 level.
News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 26, 2015
20:50 EDTCELGBernstein to hold a conference
Subscribe for More Information
07:39 EDTCELGCelgene management to meet with SunTrust
Group dinner to be held in New York on May 27 hosted by SunTrust.
May 21, 2015
08:08 EDTCELGAgios Pharmaceuticals to present data at 20th Congress of EHA
Subscribe for More Information
May 19, 2015
08:17 EDTCELGCelgene says patients experienced clinical remission in Phase II GED-0301 trial
Subscribe for More Information
May 18, 2015
08:44 EDTCELGCelgene data positive, says SunTrust
SunTrust believes that data presented for Celgene's GED-0301 in Crohn's indicated that the drug is effective irrespective of baseline disease severity and CRP levels.Consequently, the firm thinks the data addressed questions raised in an NEJM editorial about the drug. It keeps a $141 price target and Buy rating on the shares.
07:31 EDTCELGCelgene, Acceleron granted fast track designations for luspatercept
Subscribe for More Information
May 14, 2015
11:11 EDTCELGAnalysts divided on significance of Celgene blood cancer drug data
Subscribe for More Information
May 13, 2015
17:42 EDTCELGCelgene announces over 55 blood, solid tumor cancer study presentations at ASCO
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use